Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
Veru Inc. logo

NASDAQ · VERU

Veru Inc.

Healthcare · Biotechnology

$2.47

Down-$0.08 (-3.14%)

Updated Oct 7, 2026, 9:35 AM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
37.07M
P/E ratio
-1.13
Dividend yield
0.00%
52-week range
$2.05 – $7.33
Volume
1.52M
Avg. volume
159K

Price performance · VERU

VERU price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

VERU closed at $2.47 after 21 trading sessions, down 4.26% for the selected period.

Last close
$2.47
Period change
-4.26%
Period low
$2.32
Period high
$2.66
Daily close
View OHLC price history
VERU OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$2.54$2.75$2.44$2.471.52M
Oct 5, 2026$2.51$2.62$2.50$2.5588.77K
Oct 2, 2026$2.56$2.56$2.50$2.51104.96K
Oct 1, 2026$2.65$2.65$2.53$2.5470.68K
Sep 30, 2026$2.58$2.70$2.51$2.66183K
Sep 29, 2026$2.53$2.58$2.50$2.5633.1K
Sep 28, 2026$2.52$2.57$2.5102$2.525101.37K
Sep 25, 2026$2.55$2.57$2.50$2.54116.07K
Sep 24, 2026$2.42$2.52$2.4199$2.5187.41K
Sep 23, 2026$2.49$2.51$2.425$2.4694.86K
Sep 22, 2026$2.46$2.52$2.421$2.50121.37K
Sep 21, 2026$2.44$2.49$2.43$2.44158.32K
Sep 18, 2026$2.39$2.44$2.36$2.41103.03K
Sep 17, 2026$2.35$2.4001$2.3489$2.3993.92K
Sep 16, 2026$2.34$2.37$2.3112$2.32130.34K
Sep 15, 2026$2.36$2.36$2.29$2.34125.37K
Sep 14, 2026$2.41$2.44$2.34$2.34210.97K
Sep 11, 2026$2.52$2.5299$2.43$2.44245.31K
Sep 10, 2026$2.52$2.53$2.46$2.50182.73K
Sep 9, 2026$2.59$2.59$2.48$2.48265.75K
Sep 8, 2026$2.81$2.8494$2.55$2.581.34M

Latest VERU news

The latest Smart Investors Daily articles mentioning VERU.

Stock researchCompany · Overview

VERU research

Overview

Company profile and research snapshot.

Company profile

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.00
Implied upside
—
Analysts
—
VERU recent ratings
DateFirmRatingTarget
Jun 4, 2026Canaccord GenuityBuy—
May 15, 2026OppenheimerOutperform—
Dec 18, 2025Canaccord GenuityBuy—
Aug 13, 2025Raymond JamesOutperform—
Jan 2, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

--New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer cell line which is a drug concentration that can be achieved with current sabizabulin human dosing with good safety-- --Oral sabizabulin had a good safety profile and promising efficacy in previous first-in-man Phase 1b/2 clinical study of 80 subjects with castration resistant and taxane resistant met

Yahoo · Sep 2, 2026

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

MIAMI, FL, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the upcoming 2026 Cantor Global Healthcare Conference, in New York City, New York, on September 9, 2026 from 2:10 pm – 2:40 pm Easte

Yahoo · Aug 10, 2026

Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients – -- Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027-- -- In June 2026 Company announced a clinical supply agreement with Novo Nordisk for its Phase 2b PLATEAU clinical trial -- -- In August 2026 Company announced USPTO notice of allowance for key U.S. patent for enobosarm and semaglutide; when issued, U.S. patent

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By